Web Analytics
Cổ phiếu NVS (NYSE) | NOVARTIS AG ADR – Phân tích Deepscope
MARKET

Select Market Data Region

NVS — NOVARTIS AG ADR (Healthcare >> Drug Manufacturers - General)

NVS FAQ

What is NVS's P/E ratio?

NOVARTIS AG ADR (NVS) currently trades at a P/E ratio of 20.25.

What is NVS's ROE?

NOVARTIS AG ADR reports a Return on Equity (ROE) of 35.14%.

What is NVS's dividend yield?

NOVARTIS AG ADR offers a dividend yield of 3.30%.

What is NVS's Deepscope Quality Score?

Deepscope rates NVS's overall financial quality at 92 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy NVS?

Deepscope's AI Timing Score for NVS is 29 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does NVS belong to?

NOVARTIS AG ADR is classified under the Healthcare >> Drug Manufacturers - General sector on the NYSE exchange.

Stock Check   *Daily update data at 9:30 AM*
(Price: 2026-06-04 | FS: 2026-03-31)

NVS

NOVARTIS AG ADR
USD 148.40
4.74 (3.30%) Day Change
20.25
P/E
1.18
D/E
35.1%
ROE
11.4%
ROA
3.30%
Div Yield
0.47
PEG
USD 148.40
Price
4.74 (3.30%)
Day Change
NEWS SCORE: 87

NVS Chất lượng tổng thể của cố phiếu Xuất sắc ( Chất lượng = 92) nhưng Thời điểm mua ...(Sign In to See)...

92

QUALITY

Signal
OUTPERFORM
Signal Description
Company financial health is Good
Reason
ROA quá thấp so với ROE

88 Sign in

TIMING

Signal
OUTPERFORM
Signal Descri...
Good
Reason
Lorem ipsum dolor sit amet
Sign in to see timing analysis
Unlock timing signals and detailed reasons
Sign in free

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt lắm , Sức khỏe tài chính Không tốt lắm , và khả năng kiếm lợi nhuận Tốt , ...

Yếu tố Chất lượng 58%
X
X
X
X
  In Recommendations? Not in any sections
  Select Rate 0.00 From 30 days period
  Watch Rate 0.00 From 30 days period
  News Score 87
  Magic Formula Rank by ROA
820
  Magic Formula Rank by ROE
820
  Magic Formula Rank by ROIC
1044
  Price 148.40
  PBV / Sector
7.04 / 2.83
  Earning Per Share 7.33
  PE / Sector
20.25 / 23.79
  PEG or PE/Growth / Sector
0.47 / 0.07
GOOD
  Average 1M Daily Value
192.94 M
GREAT
  Average 1W Daily Value
257.30 M
GREAT
Yếu tố Kỹ thuật 14%
  MACD
  MACD Signal
  MACD Divergence
  RSI
  Stochastic Oscillator K
  Stochastic Oscillator D
  ADX
  Avg 5 day Timing Score
Sức khỏe tài chính 56%
X
X
X
X
  DE / Sector
  DE Average / Sector
  DE Change Average (%) / Sector
  Current Ratio / Sector
  Current Ratio Average / Sector
  Current Ratio Change Average (%) / Sector
  Quick Ratio / Sector
  Quick Ratio Average / Sector
  Quick Ratio Change Average (%) / Sector
  FCF/Share / Sector
  FCF/Share Average / Sector
  FCF/Share Change Average (%) / Sector
Khả năng kiếm lợi nhuận 79%
X
X
X
X
X
X
X
  GPM (%) / Sector
  GPM Average (%) / Sector
  GPM Change Average (%) / Sector
  OPM (%) / Sector
  OPM Average (%) / Sector
  OPM Change Average (%) / Sector
  NPM (%) / Sector
24.14 / 18.17
GREAT
  NPM Average (%) / Sector
24.14 / 17.77
GREAT
  NPM Change Average (%) / Sector
19.16 / 93.90
GOOD
  Asset Turnover / Sector
  Asset Turnover Average / Sector
  Asset Turnover Change Average (%) / Sector
  ROA (%) / Sector
11.42 / 8.90
  ROA Average (%) / Sector
11.21 / 8.60
  ROA Change Average (%) / Sector
31.88 / 95.12
GREAT
  ROE (%) / Sector
35.14 / 27.16
GREAT
  ROE Average (%) / Sector
27.25 / 13.13
GREAT
  ROE Change Average (%) / Sector
46.11 / 97.95
GREAT
  ROIC (%) / Sector
  ROIC Average (%) / Sector
  ROIC Change Average (%) / Sector
Lợi tức cho nhà đầu tư 33%
X
  Dividend (%) / Sector
3.30 / 2.60
GOOD
  Dividend Average (%) / Sector
3.70 / 3.43
  Dividend Change Average (%) / Sector
-5.00 / 2.29
Chi tiết đăng ký
X
  Analyze Date 2026-06-05 09:11:36
  Symbol NVS
  Name NOVARTIS AG ADR
  Sector Healthcare >> Drug Manufacturers - General
  Market NYSE
  Listed Shares 1,908.09 M
  Par Value N/A
  Calculated From Quarter
  Sign N/A
  Market Cap (M.USD) / Sector Average 274,116.49 / 233,824.82
Tin tức, Dự báo ước tính
  Estimation Consensus See at WSJ.com
  Full details See at WSJ.com
  Chart See in Chart feature
  News See at Yahoo Finance

Address: Lichtstrasse 35, Basel, Switzerland, 4056

Phone: 41 61 324 11 11

Website: https://www.novartis.com

Employees: 75,267

Sector: Healthcare >> Drug Manufacturers - General

Description: Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

ME vs SECTOR Healthcare >> Drug Manufacturers - General

NVS (ME)
Sector Peers
Bubble size = Market Cap

Click a bubble to view stock details  ·  Bubble size represents market capitalization share

News

Smart picks. Just WOW stocks/funds/ETFs. No noise like other tools.
NVS
NVS
USD 148.40 (3.30%)
+ Watch + Port Chart